These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 16167916

  • 1. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
    Ozeren M, Karahan SC, Ozgur M, Eminagaoglu S, Unsal M, Baytan S, Bozkaya H.
    Acta Obstet Gynecol Scand; 2005 Oct; 84(10):987-91. PubMed ID: 16167916
    [Abstract] [Full Text] [Related]

  • 2. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 3. Dosing time-dependent effect of raloxifene on plasma plasminogen activator inhibitor-1 concentrations in post-menopausal women with osteoporosis.
    Ando H, Otoda T, Ookami H, Nagai Y, Inano A, Takamura T, Ushijima K, Hosohata K, Matsushita E, Saito T, Kaneko S, Fujimura A.
    Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):227-32. PubMed ID: 23323567
    [Abstract] [Full Text] [Related]

  • 4. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [Abstract] [Full Text] [Related]

  • 5. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, Bayraktar F, Yesil S.
    Med Princ Pract; 2009 Sep; 18(4):266-71. PubMed ID: 19494532
    [Abstract] [Full Text] [Related]

  • 6. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
    Checa MA, Garrido A, Prat M, Conangla M, Rueda C, Carreras R.
    Maturitas; 2005 Sep 16; 52(1):70-7. PubMed ID: 16143228
    [Abstract] [Full Text] [Related]

  • 7. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.
    Cosman F, Baz-Hecht M, Cushman M, Vardy MD, Cruz JD, Nieves JW, Zion M, Lindsay R.
    Thromb Res; 2005 Sep 16; 116(1):1-13. PubMed ID: 15850603
    [Abstract] [Full Text] [Related]

  • 8. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep 16; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 9. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D.
    Thromb Res; 2006 Sep 16; 118(4):495-500. PubMed ID: 16318869
    [Abstract] [Full Text] [Related]

  • 10. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL, Graham C, Harding SA, Ludlam CA, Fox KA, Newby DE.
    Thromb Res; 2006 Sep 16; 118(2):189-97. PubMed ID: 16055173
    [Abstract] [Full Text] [Related]

  • 11. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z.
    Eur Cytokine Netw; 2007 Sep 16; 18(3):148-53. PubMed ID: 17823083
    [Abstract] [Full Text] [Related]

  • 12. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug 16; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 13. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
    Dias AR, Melo RN, Gebara OC, D'Amico EA, Nussbacher A, Halbe HW, Pinotti JA.
    Climacteric; 2005 Mar 16; 8(1):63-70. PubMed ID: 15804733
    [Abstract] [Full Text] [Related]

  • 14. Effects of raloxifene therapy on the anticoagulant system in postmenopausal women.
    Azevedo GD, Franco RF, Baggio MS, Maranhão TM, Ferriani RA, Silva de Sá MF.
    Climacteric; 2003 Jun 16; 6(2):140-5. PubMed ID: 12841884
    [Abstract] [Full Text] [Related]

  • 15. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A.
    Menopause; 2006 Jun 16; 13(3):377-86. PubMed ID: 16735934
    [Abstract] [Full Text] [Related]

  • 16. [Study of fibrinolysis inhibitors in 117 acute leukemia patients].
    Wang W, Ji CY, Ye JJ, Zhu YY, Guo DM, Ji M.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Mar 16; 29(3):183-6. PubMed ID: 18788619
    [Abstract] [Full Text] [Related]

  • 17. Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
    Shantsila E, Montoro-García S, Tapp LD, Apostolakis S, Wrigley BJ, Lip GY.
    Thromb Haemost; 2012 Jul 16; 108(1):32-40. PubMed ID: 22538774
    [Abstract] [Full Text] [Related]

  • 18. TAFI and PAI-1 levels in human sepsis.
    Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA.
    Thromb Res; 2006 Jul 16; 118(2):205-12. PubMed ID: 16009400
    [Abstract] [Full Text] [Related]

  • 19. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women.
    Vogelvang TE, Leurs JR, van der Mooren MJ, Mijatovic V, Hendriks DF, Neele SJ, Netelenbos JC, Kenemans P.
    Menopause; 2004 Jul 16; 11(1):110-5. PubMed ID: 14716191
    [Abstract] [Full Text] [Related]

  • 20. The hemorheological effects of raloxifene in postmenopausal women with osteoporosis. Results of a 3-year placebo-controlled clinical trial.
    Shand B, Gilchrist N, Blackwell T, March R.
    Clin Hemorheol Microcirc; 2002 Jul 16; 26(4):249-55. PubMed ID: 12122230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.